served on the editorial boards of several medical journals.
-- John J. Costanzi, M.D., is a principal investigator in the ONCONASE(R)
clinical trials program and internationally known in the field of
oncology. He is currently in the practice of oncology and hematology
in Austin, Texas. Formerly, he served as medical director of the
Thompson Cancer Survival Center in Knoxville, Tennessee, and as
professor of medicine and director of the cancer center for the
University of Texas Medical Branch in Galveston. He has received
numerous awards in the field of oncology and has authored over 140
papers, books and chapters in the area of clinical oncology.
The Webinar will begin at 8 a.m. EST on Nov. 29. To participate in the Webinar, click on the link posted on the Upcoming Events section of Alfacell's Web site at http://www.alfacell.com and enter 154905 for the room number. Please connect to the Webinar several minutes prior to the start time to ensure adequate time for any software download that may be necessary. The live event may also be accessed by dialing (877) 407-9205 (for U.S. callers) and (201) 689-8054 (for international callers). Questions may be asked over the telephone during the live event or e-mailed in advance to email@example.com. To access the replay, the Webinar will be available for 90 days on Alfacell's Web site at http://www.alfacell.com.
About Alfacell Corporation
Alfacell Corporation is the first company to advance a
biopharmaceutical product candidate that works in a manner similar to RNA
interference (RNAi) through late-stage clinical trials. The product
candidate, ONCONASE(R), is an RNase that overcomes
|SOURCE Alfacell Corporation|
Copyright©2007 PR Newswire.
All rights reserved